KWD
MCID: KWS002
MIFTS: 70

Kawasaki Disease (KWD) malady

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases, Bone diseases, Immune diseases

Aliases & Classifications for Kawasaki Disease

Aliases & Descriptions for Kawasaki Disease:

Name: Kawasaki Disease 54 12 50 25 56 66 52 41 3 14
Mucocutaneous Lymph Node Syndrome 12 50 24 25 56 66 42 69
Infantile Polyarteritis 24 66 69
Kawasaki Syndrome 50 25 3
Acute Febrile Mucocutaneous Lymph Node Syndrome 25 29
Kawasaki Disease, Susceptibility to 24 13
Kd 25 3
Acute Febrile Mucocutaneous Lymph Node Syndrome [mcls] 12
Acute Febrile Mcls 12
Kawasaki's Disease 12
Mlns 12
Kwd 66

Characteristics:

Orphanet epidemiological data:

56
kawasaki disease
Inheritance: Multigenic/multifactorial; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



External Ids:

OMIM 54 611775
Disease Ontology 12 DOID:13378
ICD10 33 M30.3
ICD9CM 35 446.1
MeSH 42 D009080
NCIt 47 C34825
Orphanet 56 ORPHA2331
ICD10 via Orphanet 34 M30.3
UMLS 69 C0026691

Summaries for Kawasaki Disease

OMIM : 54 Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever... (611775) more...

MalaCards based summary : Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to hepatitis and pyelonephritis, and has symptoms including fever, congestion of ocular conjunctivae and reddening of lips. An important gene associated with Kawasaki Disease is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include lymph node, heart and tongue, and related phenotypes are hematopoietic system and homeostasis/metabolism

NIH Rare Diseases : 50 kawasaki disease is a disease that involves inflammation of the blood vessels. it is typically diagnosed in young children, but older children and adults can also develop this condition. kawasaki disease begins with a fever that lasts at least five days. other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. kawasaki disease occurs most often in people of asian and pacific island descent. the cause of kawasaki disease is unknown. an infection along with genetic factors may be involved. treatment includes intravenous gamma globulin and high doses of aspirin in a hospital setting. prognosis is generally very good, but in cases of heart complications it depends on the severity of the coronary disease.  last updated: 3/9/2017

UniProtKB/Swiss-Prot : 66 Kawasaki disease: An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

MedlinePlus : 41 kawasaki disease is a rare childhood disease. it makes the walls of the blood vessels in the body become inflamed. it can affect any type of blood vessel, including the arteries, veins, and capillaries. no one knows what causes kawasaki disease. symptoms include high fever that lasts longer than 5 days swollen lymph nodes in the neck a rash on the mid-section and genital area red, dry, cracked lips and a red, swollen tongue red, swollen palms of the hands and soles of the feet redness of the eyes kawasaki disease can't be passed from one child to another. there is no single test. to diagnose it, doctors look at the signs and symptoms. they may also use an echocardiogram or other tests. it is mainly treated with medicines. rarely, medical procedures and surgery also may be used for children whose coronary arteries are affected. kawasaki disease can't be prevented. however, most children who develop the disease fully recover - usually within weeks of getting signs and symptoms. further problems are rare. nih: national heart, lung, and blood institute

CDC : 3 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

Genetics Home Reference : 25 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.

Disease Ontology : 12 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

Wikipedia : 71 Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a disease in which blood vessels... more...

Related Diseases for Kawasaki Disease

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.7 IL10 IL6 TNF
2 pyelonephritis 29.6 CRP IL10 NPPB TNF
3 congestive heart failure 29.1 IL10 IL6 MBL2 SELL TNF
4 histiocytosis 28.7 CRP ELANE HSPD1 IL6 MMP3 MMP9
5 rheumatoid arthritis 28.6 CCL2 CRP HSPD1 IL10 IL6 MMP3
6 myocardial infarction 28.3 ADM ALB CCL2 CRP IL10 IL6
7 abl1 kd-related altered drug metabolism 11.8
8 macrophage activation syndrome 11.2
9 spinal and bulbar muscular atrophy of kennedy 10.9
10 zap-70 deficiency 10.8
11 malignant hyperthermia susceptibility 1 10.8
12 kniest dysplasia 10.8
13 aneurysm 10.6
14 coronary artery aneurysm 10.5
15 congenital dyserythropoietic anemia 10.4 ALB TNF
16 coronary aneurysm 10.4
17 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
18 right atrium familial dilatation 10.3 MMP3 MMP9
19 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
20 swine influenza 10.3 CRP IL6 TNF
21 central epithelioid sarcoma 10.3 CRP MMP9 TNF
22 human immunodeficiency virus infectious disease 10.3 CRP IL6 TNF
23 cataract 10.3 ALB CRP TNF
24 cicatricial lagophthalmos 10.3 CRP IL6 TNF
25 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
26 shoulder impingement syndrome 10.3 ALB CRP IL6
27 benign neonatal seizures 10.3 CRP IL6 TNF
28 leukoplakia of vagina 10.3 IL6 MMP9 TNF
29 hypertropia 10.3 ALB CRP TNF
30 mikulicz disease 10.3 ALB IL6 TNF
31 transient tic disorder 10.3 IL10 IL6 TNF
32 neonatal hypoxic and ischemic brain injury 10.3 IL10 IL6 MMP9
33 neuropathy 10.3 CRP IL6 TNF
34 cyclosporiasis 10.3 IL10 IL6 TNF
35 hypoparathyroidism-retardation-dysmorphism syndrome 10.3 IL10 IL6 TNF
36 conduct disorder 10.3 IL10 IL6 TNF
37 gastric dilatation 10.3 IL10 IL6 TNF
38 urticaria 10.3 ALB CRP TNF
39 multiple mitochondrial dysfunctions syndrome 10.3 CRP IL10 IL6
40 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.3 IL10 IL6 TNF
41 gonococcal endophthalmia 10.3 IL10 IL6 TNF
42 ectodermal dysplasia bartalos type 10.3 IL10 IL6 TNF
43 primary ciliary dyskinesia 10.3 IL10 IL6 TNF
44 neurotic disorder 10.3 FCGR2A IL10 TNF
45 toxic myocarditis 10.3 CRP IL6 NPPB
46 hyperlipoproteinemia type iv 10.3 ALB CRP IL6
47 bladder sarcoma 10.3 ALB IL6 TNF
48 steroid dehydrogenase deficiency dental anomalies 10.3 CCL2 IL6 TNF
49 glucosephosphate dehydrogenase deficiency 10.3 ALB IL6 NPPB
50 intracranial arteriosclerosis 10.3 IL6 NPPB TNF

Graphical network of the top 20 diseases related to Kawasaki Disease:



Diseases related to Kawasaki Disease

Symptoms & Phenotypes for Kawasaki Disease

Clinical features from OMIM:

611775

Symptoms:

12
  • fever
  • congestion of ocular conjunctivae
  • reddening of lips
  • reddening of oral cavity
  • protuberance of tongue papillae
  • edema of extremities

Human phenotypes related to Kawasaki Disease:

56 32 (show all 37)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Occasional (29-5%) HP:0002829
2 fatigue 56 32 Frequent (79-30%) HP:0012378
3 edema 56 32 Frequent (79-30%) HP:0000969
4 fever 56 32 Frequent (79-30%) HP:0001945
5 abdominal pain 56 32 Frequent (79-30%) HP:0002027
6 diarrhea 56 32 Frequent (79-30%) HP:0002014
7 nausea and vomiting 56 32 Occasional (29-5%) HP:0002017
8 recurrent pharyngitis 56 32 Very frequent (99-80%) HP:0100776
9 ptosis 56 32 Occasional (29-5%) HP:0000508
10 arthritis 56 32 Frequent (79-30%) HP:0001369
11 proteinuria 56 32 Very frequent (99-80%) HP:0000093
12 cranial nerve paralysis 56 32 Occasional (29-5%) HP:0006824
13 arrhythmia 56 32 Occasional (29-5%) HP:0011675
14 hepatitis 56 32 Occasional (29-5%) HP:0012115
15 irritability 56 32 Occasional (29-5%) HP:0000737
16 abnormality of the heart valves 56 32 Frequent (79-30%) HP:0001654
17 congestive heart failure 56 32 Occasional (29-5%) HP:0001635
18 jaundice 56 32 Occasional (29-5%) HP:0000952
19 migraine 56 32 Occasional (29-5%) HP:0002076
20 dilatation of the ascending aorta 56 32 Occasional (29-5%) HP:0005111
21 leukocytosis 56 32 Frequent (79-30%) HP:0001974
22 cheilitis 56 32 Very frequent (99-80%) HP:0100825
23 erythema 56 32 Very frequent (99-80%) HP:0010783
24 pericarditis 56 32 Frequent (79-30%) HP:0001701
25 myocarditis 56 32 Occasional (29-5%) HP:0012819
26 conjunctivitis 56 32 Very frequent (99-80%) HP:0000509
27 skin rash 56 32 Very frequent (99-80%) HP:0000988
28 meningitis 56 32 Occasional (29-5%) HP:0001287
29 vasculitis 56 32 Very frequent (99-80%) HP:0002633
30 cholecystitis 56 32 Occasional (29-5%) HP:0001082
31 lymphadenopathy 56 32 Very frequent (99-80%) HP:0002716
32 glossitis 56 32 Frequent (79-30%) HP:0000206
33 abnormality of nail color 56 32 Frequent (79-30%) HP:0100643
34 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 56 32 Occasional (29-5%) HP:0011658
35 aseptic leukocyturia 56 32 Occasional (29-5%) HP:0100586
36 interstitial pulmonary disease 56 Occasional (29-5%)
37 interstitial pulmonary abnormality 32 HP:0006530

UMLS symptoms related to Kawasaki Disease:


angina pectoris, chest pain, edema, exanthema, pruritus

MGI Mouse Phenotypes related to Kawasaki Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 ADM ELANE FCGR2A IL10 IL6 ITPKC
2 homeostasis/metabolism MP:0005376 10.17 ADM ALB CRP ELANE IL10 IL6
3 immune system MP:0005387 10.16 IL10 IL6 ITPKC MBL2 MMP3 MMP9
4 cardiovascular system MP:0005385 10.13 MYD88 SELE SELL TIMP1 TNF ADM
5 endocrine/exocrine gland MP:0005379 10.06 ADM ALB IL10 IL6 ITPKC MYD88
6 liver/biliary system MP:0005370 9.7 ADM ALB IL10 IL6 SELE SELL
7 neoplasm MP:0002006 9.61 MMP9 MYD88 SELL TIMP1 TNF ALB
8 respiratory system MP:0005388 9.28 ADM IL10 IL6 MMP9 MYD88 SELE

Drugs & Therapeutics for Kawasaki Disease

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 487)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
2
Cilostazol Approved Phase 4 73963-72-1 2754
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
5
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
6
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
7
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
8
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
9
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
10
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
11
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
12
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
13
Alogliptin Approved Phase 4,Phase 3,Phase 2 850649-61-5 11450633
14
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
15
Vildagliptin Approved, Investigational Phase 4,Phase 3 274901-16-5 6918537
16
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
rituximab Approved Phase 4 174722-31-7 10201696
20
Saxagliptin Approved Phase 4,Phase 2,Phase 3 361442-04-8 11243969
21
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
22
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
23 Analgesics Phase 4,Phase 3,Phase 2
24 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
25 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
28 Antipyretics Phase 4,Phase 3,Phase 2
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Bronchodilator Agents Phase 4,Phase 3,Phase 2
32 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
33 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
34 Neuroprotective Agents Phase 4,Phase 3
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Phosphodiesterase 3 Inhibitors Phase 4
37 Phosphodiesterase Inhibitors Phase 4
38 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
39 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Respiratory System Agents Phase 4,Phase 3,Phase 2
41 Vasodilator Agents Phase 4,Phase 3,Phase 2
42 Adrenergic beta-Antagonists Phase 4,Phase 3
43
Angiotensin II Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7 65143 172198
44 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
45 Angiotensinogen Phase 4,Phase 3,Phase 2
46 Antihypertensive Agents Phase 4,Phase 3,Phase 2
47 calcium channel blockers Phase 4,Phase 3,Phase 2
48 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Anticholesteremic Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 406)
id Name Status NCT ID Phase
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4
2 Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease Completed NCT01524939 Phase 4
3 Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease Completed NCT00190580 Phase 4
4 Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients Completed NCT01325935 Phase 4
5 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4
6 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study) Completed NCT00250380 Phase 4
7 INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy Completed NCT00153088 Phase 4
8 PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin Completed NCT02273908 Phase 4
9 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients Completed NCT01190007 Phase 4
10 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT02417935 Phase 4
11 A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Recruiting NCT02951234 Phase 4
12 The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics Recruiting NCT02316886 Phase 4
13 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4
14 Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus Recruiting NCT03014479 Phase 4
15 A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Recruiting NCT03053427 Phase 4
16 Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) Active, not recruiting NCT01897532 Phase 4
17 Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA Active, not recruiting NCT02589626 Phase 4
18 Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus Active, not recruiting NCT02589639 Phase 4
19 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC Unknown status NCT01640808 Phase 3
20 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
21 Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Unknown status NCT01214343 Phase 3
22 Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial Completed NCT02298062 Phase 3
23 Different Doses of IVIG for Kawasaki Disease Completed NCT02439996 Phase 3
24 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Completed NCT00162032 Phase 3
25 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Completed NCT00760435 Phase 3
26 Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease Completed NCT01596335 Phase 3
27 Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network Completed NCT00132080 Phase 3
28 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
29 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3
30 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3
31 Acarbose and Secondary Prevention After Coronary Stenting Completed NCT00221156 Phase 3
32 Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) Completed NCT01614886 Phase 3
33 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. Completed NCT02296138 Phase 3
34 A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants Completed NCT02337738 Phase 2, Phase 3
35 Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00876694 Phase 3
36 Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00794157 Phase 3
37 A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants Completed NCT02337764 Phase 3
38 Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01285492 Phase 3
39 Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients Completed NCT02629965 Phase 3
40 Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT01069289 Phase 3
41 Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT01047553 Phase 3
42 Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00392899 Phase 3
43 A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3
44 Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease Completed NCT01539031 Phase 3
45 Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU Completed NCT00628862 Phase 3
46 Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD) Completed NCT01441440 Phase 3
47 Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder Completed NCT01355081 Phase 3
48 Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01431287 Phase 3
49 Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients Completed NCT01119937 Phase 3
50 Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder Completed NCT01395147 Phase 3

Search NIH Clinical Center for Kawasaki Disease

Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

Genetic tests related to Kawasaki Disease:

id Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome 29
2 Kawasaki Disease, Susceptibility to 24 ITPKC

Anatomical Context for Kawasaki Disease

MalaCards organs/tissues related to Kawasaki Disease:

39
Lymph Node, Heart, Tongue, Eye, Skin, Endothelial, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Kawasaki Disease:

18
Body

Publications for Kawasaki Disease

Articles related to Kawasaki Disease:

(show top 50) (show all 1101)
id Title Authors Year
1
Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children. ( 28461824 )
2017
2
Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. ( 28089146 )
2017
3
Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. ( 28062554 )
2017
4
Observational study of Interleukin-21 (IL-21) does not distinguish Kawasaki disease from other causes of fever in children. ( 28427414 )
2017
5
Elevated serum YKL-40 levels in patients with Kawasaki disease. ( 27881022 )
2017
6
Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up - CORRIGENDUM. ( 28532518 )
2017
7
TNF-I+ is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. ( 28526535 )
2017
8
High-dose aspirin for Kawasaki disease: outdated myth or effective aid? ( 28079513 )
2017
9
Distinct Distribution of Immunocytes in a Retropharyngeal Lymphadenopathy Associated with Kawasaki Disease: A Case Study Compared with Tonsillitis. ( 28467980 )
2017
10
Z-score of Mitral Annular Plane Systolic Excursion is a Useful Indicator of Evaluation of Left Ventricular Function in Patients with Acute-Phase Kawasaki Disease. ( 28456832 )
2017
11
Allograft Inflammatory Factor-1 Links T-Cell Activation, Interferon Response, and Macrophage Activation in Chronic Kawasaki Disease Arteritis. ( 28505365 )
2017
12
The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease. ( 28081636 )
2017
13
A Case of Hemophagocytic Lymphohistiocytosis and Kawasaki Disease: Concurrent or Overlapping Diagnoses? ( 28452857 )
2017
14
Heart Transplantation in a Toddler with Cardiac Kawasaki Disease. ( 28473974 )
2017
15
Vascular function long term after Kawasaki disease: another piece of the puzzle? ( 28446266 )
2017
16
Association of PECAM-1 Gene Polymorphisms with Kawasaki Disease in Chinese Children. ( 28512385 )
2017
17
Simultaneous development of Kawasaki disease following acute human adenovirus infection in monozygotic twins: A case report. ( 28511718 )
2017
18
Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children. ( 28498302 )
2017
19
Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. ( 28061462 )
2017
20
Pathogenetic determinants in Kawasaki disease: the haematological point of view. ( 28063205 )
2017
21
Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease. ( 28069066 )
2017
22
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease. ( 28079915 )
2017
23
Atypical desquamation in a 2.5-year-old boy with Kawasaki disease: A case report. ( 28465804 )
2017
24
Retrospective analysis of risk factors associated with Kawasaki disease in China. ( 28514726 )
2017
25
Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. ( 28478386 )
2017
26
Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease: Application Using a Random Forest Classifier. ( 28441265 )
2017
27
Mid-term Risk for Subclinical Atherosclerosis and Chronic Myocarditis in Children with Kawasaki Disease and Transient Coronary Abnormalities. ( 28512721 )
2017
28
A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs. ( 28467514 )
2017
29
Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker. ( 28417923 )
2017
30
ST-elevation myocardial infarction in a young adult secondary to giant coronary aneurysm thrombosis: an important sequela of Kawasaki disease and a management challenge. ( 26791126 )
2016
31
Suppressive influence of seasonal influenza epidemic on Kawasaki disease onset. ( 28049962 )
2016
32
Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes. ( 28043685 )
2016
33
Kawasaki disease associated with Mycoplasma pneumoniae. ( 27609267 )
2016
34
Usefulness of Single Photon Emission Computed Tomography/Computed Tomography Fusion-Hybrid Imaging to Evaluate Coronary Artery Disorders in Patients with a History of Kawasaki Disease. ( 27180792 )
2016
35
Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis. ( 27160104 )
2016
36
The different cutaneous presentations in three cases of Kawasaki disease as confounding factor of diagnosis. ( 27654745 )
2016
37
One small step for exosomes, one giant leap for Kawasaki disease. ( 27132470 )
2016
38
Systemic-onset juvenile idiopathic arthritis or incomplete Kawasaki disease: a diagnostic challenge. ( 27782865 )
2016
39
Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease. ( 27171184 )
2016
40
Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease. ( 26761773 )
2016
41
Importance of anatomical dominance in the evaluation of coronary dilatation in Kawasaki disease. ( 27640521 )
2016
42
Efficacy of Four Scoring Systems in Predicting Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease in a Children's Hospital in Beijing, North China. ( 28043682 )
2016
43
Usefulness of anterior uveitis as an additional tool for diagnosing incomplete Kawasaki disease. ( 27186227 )
2016
44
Crystalline keratopathy due to intravenous immunoglobulin in a 12-year-old girl with Kawasaki disease. ( 27667371 )
2016
45
Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease. ( 27064036 )
2016
46
Variations in ORAI1 Gene Associated with Kawasaki Disease. ( 26789410 )
2016
47
Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. ( 27997519 )
2016
48
Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities. ( 27610181 )
2016
49
Myeloperoxidase genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. ( 26066543 )
2016
50
Giant Coronary Aneurysms in a one-month-old Infant with Kawasaki Disease. ( 27641973 )
2016

Variations for Kawasaki Disease

Expression for Kawasaki Disease

Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for Kawasaki Disease

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CCL2 CRP ELANE FCGR2A IL10 IL6
2
Show member pathways
13.36 CCL2 IL10 IL6 MMP3 MMP9 MYD88
3
Show member pathways
12.9 CCL2 IL10 IL6 MBL2 MMP9 MYD88
4
Show member pathways
12.86 CCL2 IL6 MMP9 SELE TNF
5
Show member pathways
12.59 CCL2 IL10 IL6 TIMP1 TNF
6
Show member pathways
12.35 ALB CCL2 CRP IL6 TNF
7
Show member pathways
12.34 CCL2 IL6 MMP3 MMP9 TNF
8
Show member pathways
12.25 FCGR2A IL10 MYD88 TNF
9 12.22 ELANE IL6 MMP3 MMP9
10 12.21 FCGR2A HSPD1 IL10 IL6 MYD88 TNF
11 12.17 HSPD1 IL10 IL6 TNF
12 12.09 CCL2 MMP9 SELE TNF
13 12 CCL2 FCGR2A IL6 MMP9 TNF
14 11.98 FCGR2A IL10 IL6 SELL TNF
15 11.92 CCL2 IL6 SELE TNF
16
Show member pathways
11.89 ELANE MMP3 MMP9 TIMP1 TNF
17 11.88 CCL2 IL6 MMP3 TNF
18 11.85 CCL2 MMP3 MMP9 TIMP1
19 11.83 CCL2 IL6 MMP3 MMP9 SELE TNF
20 11.77 IL10 IL6 SELL TNF
21 11.77 IL10 IL6 MYD88 TNF
22 11.71 FCGR2A IL10 IL6 TNF
23 11.64 MMP3 MMP9 TIMP1
24 11.63 CCL2 IL6 MMP9 TIMP1 TNF
25
Show member pathways
11.6 IL6 MMP3 MMP9 SELE TNF
26 11.59 FCGR2A IL10 MBL2
27 11.59 HSPD1 IL6 MYD88 TNF
28 11.56 CCL2 IL10 IL6 MMP3 MMP9 TIMP1
29 11.52 ELANE IL6 MMP9 TNF
30 11.46 CCL2 IL10 IL6 TIMP1 TNF
31 11.36 IL10 IL6 TNF
32 11.35 CCL2 IL6 MMP9
33 11.29 IL10 IL6 TNF
34 11.25 ELANE MMP3 MMP9 SELE SELL
35 11.2 CCL2 IL10 IL6 TNF
36 11.16 CCL2 MMP9 MYD88 TIMP1
37 11.1 IL10 IL6 MYD88 SELE TNF
38 11.05 CRP IL6 TNF
39 10.79 CCL2 IL10 IL6 MYD88 SELE TNF

GO Terms for Kawasaki Disease

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ADM ALB CCL2 CRP ELANE IL10
2 extracellular space GO:0005615 9.5 ADM ALB CCL2 CRP ELANE HSPD1

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.96 ELANE MMP9 SELE SELL TNF
2 defense response to bacterium GO:0042742 9.95 ELANE IL10 MBL2 S100A12 TNF
3 inflammatory response GO:0006954 9.92 CCL2 CRP IL10 IL6 MYD88 S100A12
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL6 MYD88 S100A12 TNF
5 aging GO:0007568 9.91 ADM CCL2 IL10 IL6 TIMP1
6 cellular response to lipopolysaccharide GO:0071222 9.89 CCL2 IL10 IL6 TNF
7 response to wounding GO:0009611 9.87 ADM CCL2 IL6
8 response to insulin GO:0032868 9.86 ADM IL10 IL6
9 positive regulation of MAP kinase activity GO:0043406 9.85 ELANE S100A12 TNF
10 extracellular matrix disassembly GO:0022617 9.84 ELANE MMP3 MMP9 TIMP1
11 humoral immune response GO:0006959 9.83 CCL2 IL6 TNF
12 response to heat GO:0009408 9.83 CCL2 HSPD1 IL6
13 response to activity GO:0014823 9.81 CCL2 HSPD1 IL10
14 response to cold GO:0009409 9.8 ADM HSPD1 IL6
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 ELANE IL6 MYD88 TNF
16 monocyte chemotaxis GO:0002548 9.79 CCL2 IL6 S100A12
17 cellular response to estradiol stimulus GO:0071392 9.78 CCL2 IL10 IL6
18 acute-phase response GO:0006953 9.77 CRP IL6 MBL2
19 response to organic substance GO:0010033 9.77 ADM HSPD1 IL10 TIMP1 TNF
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 CCL2 MYD88 TNF
21 response to glucocorticoid GO:0051384 9.73 ADM CCL2 HSPD1 IL10 IL6 TNF
22 positive regulation of interleukin-6 production GO:0032755 9.71 HSPD1 IL6 MYD88 TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
24 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 IL10 MMP9 TNF
25 positive regulation of chemokine biosynthetic process GO:0045080 9.69 MYD88 TNF
26 branching involved in labyrinthine layer morphogenesis GO:0060670 9.68 ADM IL10
27 opsonization GO:0008228 9.68 CRP MBL2
28 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 ELANE TNF
29 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
30 response to yeast GO:0001878 9.67 ELANE IL6
31 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.66 IL10 TIMP1
32 response to peptidoglycan GO:0032494 9.65 IL6 MYD88
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
34 leukocyte migration involved in inflammatory response GO:0002523 9.65 CCL2 ELANE SELE
35 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.64 IL6 TNF
36 regulation of vascular endothelial growth factor production GO:0010574 9.63 CCL2 IL6
37 defense response to Gram-positive bacterium GO:0050830 9.63 ADM CRP IL6 MBL2 MYD88 TNF
38 negative regulation of lipid storage GO:0010888 9.61 CRP IL6 TNF
39 receptor biosynthetic process GO:0032800 9.58 IL10 TNF
40 negative regulation of chemokine biosynthetic process GO:0045079 9.58 ELANE IL6
41 response to lipopolysaccharide GO:0032496 9.56 ADM CCL2 ELANE HSPD1 IL10 IL6
42 negative regulation of growth of symbiont in host GO:0044130 9.02 ELANE IL10 MBL2 MYD88 TNF
43 neutrophil degranulation GO:0043312 10.09 ELANE FCGR2A MMP9 S100A12 SELL
44 positive regulation of apoptotic process GO:0043065 10.03 ADM HSPD1 IL6 MMP9 TNF
45 negative regulation of apoptotic process GO:0043066 10 ALB HSPD1 IL10 IL6 MMP9 MYD88

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CCL2 IL10 IL6 TIMP1 TNF
2 endopeptidase activity GO:0004175 9.5 ELANE MMP3 MMP9
3 receptor binding GO:0005102 9.43 ADM CCL2 IL6 MBL2 MYD88 NPPB
4 protease binding GO:0002020 9.02 ELANE HSPD1 SELL TIMP1 TNF
5 protein binding GO:0005515 10.21 ADM ALB CRP ELANE FCGR2A HSPD1

Sources for Kawasaki Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....